Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Looking for leg up in hemophilia B gene therapy race, uniQure flashes data that helped lead to $2B CSL deal

5 years ago

MPM, DCVC Bio back $53M round for a bold concept: Let patients make their own CAR-T in vivo

5 years ago

Jim Wilson offers a safer solution to some of the industry's gene therapy woes

5 years ago

UCB is beefing up its gene therapy ops with back-to-back deals to buy a startup and sign up a university spinout for discovery work

5 years ago

Under a new CEO, German CDMO Vibalogics bets $150M and 110,000 square feet on the gene therapy revolution

5 years ago

Bayer fronts $65M Series A for Metagenomi, a gene therapy biotech aiming to find new CRISPR enzymes

5 years ago

'We're not a vant': Axovant seeks to forget the past as the company rebrands to Sio Gene Therapies

5 years ago

DSMB hits pause on Voyager's Neurocrine-partnered Parkinson's gene therapy

5 years ago

Legend Biotech has a new chairwoman and permanent CEO. But where is Frank Zhang?

5 years ago

Decibel Therapeutics raises $82M as Laurence Reid looks to steer gene therapy pivot

5 years ago

Citing pandemic, Sarepta defers much-anticipated DMD gene therapy PhIII, will head to regulators after 10-person study

5 years ago

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

5 years ago

Patient death mars latest cut of data from Allogene's off-the-shelf CAR-T

5 years ago

Vertex, fresh off an R&D miss, flashes data suggesting their sickle cell CRISPR therapy is working

5 years ago

JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China

5 years ago

Promising mRNA tech comes with regulatory, CMC headaches

5 years ago

Eyeing commercialization, a Shanghai-based CAR-T startup nabs a $186M megaround

5 years ago

Sana Biotechnology snags Oscine, adding cell therapy leader Steve Goldman to its star-studded staff

5 years ago

Bellicum slashes 79% of staffers after early data quash hope around next-gen CAR-T

5 years ago

Novartis buys a new gene therapy for vision loss, and this is one preclinical venture that didn't come cheap

5 years ago

Bayer buys a biotech ‘race horse’ with a $4B deal — $2B in cash — aimed at going big into gene therapy

5 years ago

Ultragenyx injects $40M to grab Solid's microdystrophin transgene — while sidestepping the AAV9 vector that stirred up safety fears

5 years ago

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

5 years ago

Bo Cumbo jumps from the top commercial post at Sarepta to the helm of a gene therapy startup with some influential backers, big plans and $107M

5 years ago

First page Previous page 42 43 444546 47 48 Next page Last page